Tumor response was observed in 100% of crizotinib naive patients, in 74% of crizotinib pre-treated patients and 83% of crizotinib-naive or crizotinib-pre-treated ALK-rearranged NSCLC with active, measurable, intracranial metastases. The gene discussed is ALK; the disease is neoplasm.